Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia
C Boutari, A Karagiannis, VG Athyros - Expert review of …, 2021 - Taylor & Francis
Introduction: Statins are powerful lipid-lowering agents which reduce cardiovascular (CV)–
related morbidity and mortality. However, a large proportion of patients cannot attain the …
related morbidity and mortality. However, a large proportion of patients cannot attain the …
[PDF][PDF] Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia
C Boutari, A Karagiannis, VG Athyros - 2021 - researchgate.net
Introduction: Statins are powerful lipid-lowering agents which reduce cardiovascular (CV)–
related morbidity and mortality. However, a large proportion of patients cannot attain the …
related morbidity and mortality. However, a large proportion of patients cannot attain the …
Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia.
C Boutari, A Karagiannis, VG Athyros - Expert Review of …, 2021 - europepmc.org
Introduction: Statins are powerful lipid-lowering agents which reduce cardiovascular (CV)-
related morbidity and mortality. However, a large proportion of patients cannot attain the …
related morbidity and mortality. However, a large proportion of patients cannot attain the …
Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia
C Boutari, A Karagiannis… - Expert review of …, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction: Statins are powerful lipid-lowering agents which reduce cardiovascular (CV)-
related morbidity and mortality. However, a large proportion of patients cannot attain the …
related morbidity and mortality. However, a large proportion of patients cannot attain the …